PSMB10 and diffuse large B-cell lymphoma: The mechanism(s) for ixazomib effectiveness in high risk DLBCL subtypes such as DHL is still unknown, but could possibly be due to higher immunoproteasome activity in these cells, as our study shows that ixzomib treatments were more responsive to cells with higher immunoproteasome subunit MECL1 activity, particularly in the GCB-DLBCL subtype.